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BACKGROUND: There is clinical evidence to suggest that tumour necrosis factor-a (TNF-a) may be a therapeutic target in renal cell
carcinoma (RCC). Multi-targeted kinase inhibitors, such as sorafenib and sunitinib, have become standard of care in advanced RCC.
The anti-TNF-a monoclonal antibody infliximab and sorafenib have differing cellular mechanisms of action. We conducted a phase I/II
trial to determine the safety and efficacy of infliximab in combination with sorafenib in patients with advanced RCC.
METHODS: Eligible patients were systemic treatment-naive or had received previous cytokine therapy only. Sorafenib and infliximab
were administered according to standard schedules. The study had two phases: in phase I, the safety and toxicity of the combination
of full-dose sorafenib and two dose levels of infliximab were evaluated in three and three patients, respectively, and in phase II, further
safety, toxicity and efficacy data were collected in an expanded patient population.
RESULTS: Acceptable safety was reported for the first three patients (infliximab 5mgkg
 1) in phase 1. Sorafenib 400mg twice daily and
infliximab 10mgkg
 1 were administered to a total of 13 patients (three in phase 1 and 10 in phase 2). Adverse events included grade
3 hand–foot syndrome (31%), rash (25%), fatigue (19%) and infection (19%). Although manageable, toxicity resulted in 75% of the
patients requiring at least one dose reduction and 81% requiring at least one dose delay of sorafenib. Four patients were progression-
free at 6 months (PFS6 31%); median PFS and overall survival were 6 and 14 months, respectively.
CONCLUSION: Sorafenib and infliximab can be administered in combination, but a significant increase in the numbers of adverse events
requiring dose adjustments of sorafenib was observed. There was no evidence of increased efficacy compared with sorafenib alone
in advanced RCC. The combination of sorafenib and infliximab does not warrant further evaluation in patients with advanced RCC.
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The treatment of metastatic renal cell carcinoma (RCC) has
evolved rapidly since 2006 with the clinical development of
targeted agents, such as sorafenib and sunitinib. Sorafenib is an
inhibitor of multiple tyrosine kinases, including vascular endo-
thelial growth factor (VEGF) and platelet derived growth factor
(PDGF) receptors; the recommended dose is 400mg twice daily;
dose-limiting toxicities include diarrhoea, fatigue and skin toxicity
(Strumberg et al, 2005). The activity of sorafenib in patients with
advanced RCC has been demonstrated in the target phase III
placebo-controlled trial in cytokine-pretreated patients (Escudier
et al, 2007) that led to registration of the drug in this indication.
A recently published randomised phase II study in previously
untreated patients, however, did not show a progression-free
survival (PFS) advantage for sorafenib in comparison with
interferon-a (5.7 vs 5.6 months, respectively) (Escudier et al, 2009).
Infliximab is a chimeric human–mouse monoclonal antibody to
tumour necrosis factor-a (TNF-a), a pro-inflammatory cytokine.
Infliximab prevents TNF-a binding to receptors, thereby neutralising
its activity. In-vitro models suggest that this can induce cell death by
complement-mediated lysis through the interaction with membrane-
bound TNF-a (Scallon et al, 1995). Although animal studies using
TNF-a in high dose can induce significant anti-cancer effects,
(Locksley et al, 2001; Balkwill, 2002, 2006), lower levels of TNF-a
may be involved in cancer promotion, tumour growth and metastasis,
either directly or by a network of cytokines, chemokines and matrix
metalloproteinases (Moore et al,1 9 9 9 ;L o c k s l e yet al, 2001; Balkwill,
2006). TNF-a also has a role in cancer cachexia and fatigue and is a
putative autocrine and paracrine growth factor in RCC (Mizutani
et al, 1994; Balkwill, 2006).
Infliximab is licensed for use in inflammatory diseases at doses
of 3–10mgkg
 1. Large randomised trials have documented the
safety of infliximab; the most common adverse events include
injection site or infusion reactions, development of anti-nuclear
antibodies and infection (Lichtenstein et al, 2009). In 2007, we
published the results of two sequential phase II trials documenting
the activity of the anti-TNF-a antibody infliximab at dose levels
of 5 and 10mgkg
 1 in patients with metastatic RCC previously
treated with cytokine therapy (Harrison et al, 2006). Of the
37 patients treated, three patients achieved a partial response and
46% achieved clinical benefit (partial response or stable disease
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s43 months), which was considered clinically significant given that
all patients had documented disease progression at the time of
study entry. Infliximab was well tolerated. A dose of 10mgkg
 1
was recommended for further evaluation in the treatment of
advanced RCC. Although outcomes for patients with advanced
RCC have improved significantly in recent years with the
development of novel targeted systemic therapies, almost all
patients develop resistance to treatment and cure is rarely seen
(Miller and Larkin 2009). Consequently there remains a need to
induce longer lasting remissions, to overcome resistance and to
improve survival. A potential approach to this is to combine active
agents, and given that sorafenib and infliximab have different
mechanisms of action and have non-overlapping toxicity profiles,
we carried out a phase I/II study to explore the safety and efficacy
of this combination at the full single agent doses of both drugs.
PATIENTS AND METHODS
Study objectives and patient selection
Multi-targeted kinase inhibitors and anti-TNF-a therapy have not
previously been combined in humans, so the study was conducted
in two parts: phase I and phase II. The objective of phase I was to
assess the safety and toxicity of the combination of two dose levels
of infliximab and full-dose sorafenib. The objective of phase II
was to carry out a preliminary assessment of the efficacy of the
combination and to gather further safety and toxicity data. Study
inclusion criteria included: histologically proven metastatic RCC;
measurable disease according to RECIST 1.0 (Therasse et al, 2000);
either systemic treatment-naive or have progressed after immuno-
therapy; Eastern Cooperative Oncology Group performance status
of 0 or 1; adequate bone marrow, liver and renal function.
Study design and statistical methods
This trial was conducted at The Royal Marsden Hospital NHS
Foundation Trust and recruited between June 2007 and February
2009. Approval for the study was obtained from the Local Research
Ethics Committee and Regulatory Authority. All patients provided
written informed consent before study entry.
Phase I was carried out according to a standard three and three
design, respecyively: the first cohort of three patients was treated at
full-dose sorafenib 400mg twice per day (bd) orally and infliximab
5mgkg
 1 intravenously. In the absence of significant safety and
toxicity problems in the first cohort, the dose of infliximab was to
be escalated to the full dose of 10mgkg
 1 in combination with
sorafenib 400mg bd in the second cohort of three patients.
Sorafenib was started on day 0 with standard dose reductions and
interruptions for toxicity as necessary. Infliximab was adminis-
tered at weeks 1, 3 and 7 and then every 4 weeks. In the event of
dose delays due to toxicity from one agent, administration of the
other agent continued in the absence of contraindications.
Phase II was carried according to a Simon two-stage design;
the primary end point was the proportion of patients who were
progression-free at 6 months (PFS6). Secondary endpoints
included toxicity, overall survival and response rate at 12 weeks.
It was assumed that if the proportion of patients alive and PFS6
was o47% then the combination of sorafenib and infliximab did
not demonstrate additive activity. According to Simon, the
detection of a PFS6 rate of X47% with a probability of a type I
error of 5% and a type II error of 20% required the enrolment of 18
patients in stage one. Of the 18 patients, 10 or more were required
to be PFS6 to proceed to stage two. To minimise the chance
of patients being subjected to a potentially toxic treatment,
the efficacy analysis population consisted of all patients treated
in phase II and all patients in phase I treated at the same doses of
sorafenib and infliximab.
Response and toxicity assessments
Response to therapy was assessed using the Response Evaluation
Criteria in Solid Tumours (Therasse et al, 2000), with computed
tomographic scans at baseline and every 12 weeks following the
initiation of treatment. Adverse events were graded using the
National Cancer Institute Common Toxicity Criteria version 3.0.
RESULTS
A total of 16 patients were recruited; six into the phase I and 10
into the phase II parts of the study. Baseline patient characteristics
are shown in Table 1. Patients had an average age of 57 (range,
35–72), were predominantly male (13 of 16 patients) and most
(12 of 16 patients) were in the low-risk Memorial Sloan-Kettering
Cancer Centre prognostic risk category (Motzer et al, 2002).
Cytokine therapy had been administered previously to five
patients, and most patients (14 of 16 patients) had undergone
previous nephrectomy. All patients except two had clear cell
histology and all patients except one had documented disease
progression at the time of study entry. The patient who did not have
evidence of radiological progression at the time of study entry had
multiple lung metastases requiring first line systemic treatment.
In phase I, no unexpected toxicities were seen in the three
patients treated with sorafenib 400mg bd and infliximab
5mgkg
 1; the next cohort of three patients was, therefore, dosed
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sat sorafenib 400mg bd and infliximab 10mgkg
 1. One patient at
this dose level developed grade three fatigue and grade 3 rash and
the other two experienced grade 3 hand–foot–skin reaction. All of
these toxicities were considered attributable to sorafenib rather
than the combination of agents, and as a consequence these doses
were selected for further evaluation in the phase II part of the
study given our desire in the expansion to further evaluate the
efficacy and toxicity of infliximab and sorafenib at the recom-
mended therapeutic doses of both agents in RCC.
For the analysis of efficacy, data from the three patients dosed at
sorafenib 400mg bd and infliximab 10mgkg
 1 in phase I were
combined with data from the 10 patients treated in phase II.
Four of the 13 patients were PFS6 (31%); an interim efficacy
analysis was performed and the trial was closed at this point
because the pre-specified target of X10 of 18 patients achieving
PFS6 in stage one was not attainable. One patient achieved a partial
response, two patients had progressive disease and the remaining
10 patients had stable disease as their best response to treatment.
The Kaplan–Meier median PFS (Figure 1A) for all 16 patients from
phase 1 and 2 was 6 months (95% confidence interval 4.8–7.2
months) and the Kaplan–Meier median overall survival
(Figure 1B) for all patients was 14 months (95% confidence
interval 10–19 months).
One patient in phase I and three patients in phase II stopped
study treatment because of adverse reactions and two patients
remained on study treatment at the time of the last follow-up. Of
the four patients who stopped because of the adverse reactions,
two did so because of the serious infections, one because of allergic
reaction and one because of the development of multiple toxicities
that included hand–foot syndrome, fatigue and mucositis. All
other patients discontinued treatment because of the progressive
disease. Adverse events for all patients are summarised in Table 2.
There were no grade 4 adverse events and no treatment-related
deaths. Grade 3 adverse events were experienced by 13 of 16
patients and the three remaining patients all reported grade 2
adverse events. The most common grade 3 adverse events were
hand–foot syndrome (31%), rash (25%), fatigue (19%) and
infection (19%). The most frequent adverse events of any grade
were rash (88%), lymphopaenia (81%), diarrhoea (81%), alopecia
(75%) and hand–foot syndrome (75%). Serious haematological
toxicity was uncommon. Serious infection occurred in two
patients; both developed infections within primary renal tumours
and the surrounding renal parenchyma with associated abscess
formation. Allergic reactions were reported in two patients; one to
infliximab and one to sorafenib. Of 16 patients, 5 experienced dose
delays of infliximab and 13 had delays of sorafenib. A total of
12 patients had a reduction in sorafenib dose to once daily and,
of these, three had a further reduction to once every 2 days.
Table 2 Treatment-related adverse events (worst grades, all patients)
Grade 1 Grade 2 Grade 3 Grade 4 Any Grade
Adverse event n (%) n (%) n (%) n (%) n (%)
Rash 5 31 5 31 4 25 — — 14 88
Lymphopaenia 12 75 — — 1 6 — — 13 81
Diarrhoea 10 62 2 12 1 6 — — 13 81
Alopecia 10 62 2 12 — — — — 12 75
Hand–foot reaction 3 19 4 12 5 31 — — 12 75
Anaemia 8 50 2 12 1 6 — — 11 69
Fatigue/lethargy 4 25 3 19 3 19 — — 10 62
Stomatitis/mucositis 6 37 3 19 — — — — 9 56
Infection 3 19 2 12 2 12 — — 7 44
Dyspnoea 6 37 1 6 — — — — 7 44
Nausea/vomiting 4 25 1 6 1 6 — — 6 37
Flushing 5 31 — — 1 6 — — 6 37
Anorexia 4 25 1 6 — — — — 5 31
Constipation 3 19 1 6 — — — — 4 25
Leucopaenia 2 12 1 6 1 6 — — 4 25
Thrombocytopaenia 4 25 — — — — — — 4 25
Hypertension — — 3 19 1 6 — — 4 25
Neutropaenia 1 6 1 6 — — — — 2 12































N Events Median (months)
All patients 14 6 16
03 6 24 12
6 13 16
Figure 1 Kaplan–Meier plots of (A) progression-free survival (PFS) and
(B) overall survival (OS).
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sNone of the patients had a reduction in infliximab dose. We did
not observe a reduction of potentially TNF-a mediated constitu-
tional symptoms, such as anorexia or lethargy.
DISCUSSION
We investigated the safety and efficacy of combining sorafenib
with infliximab for the treatment of advanced RCC. To our
knowledge, this is the first report of the combination of a multi-
targeted kinase inhibitor with anti-TNF-a therapy in humans.
We evaluated a dose of sorafenib 400mg twice daily and
infliximab 10mgkg
 1 every 4 weeks. Only four of 13 patients
(31%) treated with this combination were free from progression
6 months after commencing treatment; this is lower than would be
predicted with sorafenib alone. We enrolled a mixture of patients
who were naive to systemic treatment and others who had
progressed after immunotherapy. The activity of sorafenib in these
settings may be regarded similar. In a randomised phase II trial of
189 previously untreated patients, the median PFS on sorafenib
was 5.7 months with an estimated PFS6 47% (Escudier et al, 2009)
and in a phase III trial of 903 previously treated patients (83% with
cytokines), the median PFS on sorafenib was 5.5 months and
estimated PFS6 43% (Escudier et al, 2007).
The lack of efficacy for the combination of sorafenib and
infliximab cannot be explained by baseline patient factors given
that the study population consisted mainly of patients of low or
intermediate Memorial Sloan-Kettering Cancer Centre risk. Two
patients had not undergone previous nephrectomy. In this study
there was a considerably higher rate of sorafenib dose reductions,
delays and treatment discontinuation in comparison with rates
reported in the literature for sorafenib alone (Escudier et al, 2007,
2009). We observed a discontinuation rate because of the adverse
reactions of 25%, a dose reduction rate for sorafenib of 75% and
a dose interruption rate for sorafenib of 81%. In comparison, in
the target study (Escudier et al, 2007) discontinuation and dose
reduction rates were 10 and 13%, respectively, with dose
interruptions in 21%. It is possible that the lower dose intensity
of sorafenib treatment in our study due to these dose adjustments
contributed to reduced efficacy, particularly as a dose-dependent
increase in efficacy of sorafenib has been reported (Amato et al,
2007; Escudier et al, 2009).
It is unclear whether the relatively lower dose intensity of
sorafenib can be attributed to increased toxicity resulting from the
concurrent administration of infliximab, or whether it is a chance
finding given the small sample size. The aim of this study was to
deliver therapeutic single agent doses of both agents in combina-
tion as sub-therapeutic doses might lead to rejection of a
potentially efficacious combination. The toxicity seen in the phase
II part of this study was higher than that reported for sorafenib
as a single agent in two pivotal trials that included 189 and 903
patients, respectively (Escudier et al, 2007, 2009). The following
adverse reactions were more frequent in our study compared with
those reported in patients treated with sorafenib in the target study
(Escudier et al, 2007); rash (88 vs 40%), diarrhoea (81 vs 43%),
alopecia (75 vs 27%), hand–foot syndrome (75 vs 30%), anaemia
(69 vs 8%), fatigue/lethargy (62 vs 37%), dyspnoea (44 vs 14%),
anorexia (31 vs 16%), nausea (37 vs 23%) and hypertension
(25 vs17%). Although most of the increased toxicity in our study
was due to an increase in grade 1 or grade 2 events, grade 3 or
4 toxicity, including rash (25 vs 1%), hand–foot syndrome (31 vs
6%) and lethargy (19 vs 5%) was also frequently observed. It is of
note that, two of our patients developed serious infections with
abscess formation in primary renal tumours/surrounding renal
parenchyma. It is possible that the use of infliximab contributed to
this given that immunosupression is a known side effect of this
agent.
This study suggests that the combination of sorafenib and
infliximab at full single dose levels should not be further evaluated
in patients with advanced RCC. However, the putative anti-tumour
activity of infliximab that has been previously demonstrated in
advanced RCC (Harrison et al, 2006) warrants further investigation
and combination with alternative agents or in subgroups of
patients should be considered.
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